TScan Therapeutics Inc (TCRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.21+11.11%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · TCRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -77.8% |
| Our one-year growth estimate | diamond | -77.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The two one-year growth estimates are about the same.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
TCRX — officer change
Dated 2026-09-30
CFO — Jason A. Amello: The filing confirms the termination of the CFO and CMO as part of a strategic reorganization, representing the loss of two senior executives.
Why it matters: These are the first two solid tumor candidates in TScan's new plan. The data can show whether they are ready for IND work.
Supportive ifTScan shares Q1 2027 data for both candidates. The results support work to enable IND filings.
Worry ifThe data are delayed past Q1 2027, or TScan stops IND-enabling work on either candidate.
Why it matters: TScan received notice that its share price did not meet Nasdaq's $1.00 minimum. A timely fix can preserve its current listing.
Worry ifA company filing confirms TScan meets Nasdaq's $1.00 minimum bid-price rule on time.
Less concerning ifTScan fails to regain compliance by the deadline, or Nasdaq moves to delist the shares.
Why it matters: An IND filing would move the new in vivo program toward human testing. TScan has planned Phase 1 trials for Q4 2027.
Supportive ifTScan files an IND for a PRAME or MAGE-A4 candidate by Q3 2027.
Worry ifNo IND is filed by the end of Q3 2027, or TScan delays the planned Q4 2027 Phase 1 start.
Why it matters: TScan plans to fund operations into Q4 2027 after a large staff cut. The earnings update can show whether cash use matches that plan.
Worry ifTScan reports enough cash and marketable securities to fund operations into Q4 2027. It confirms planned cost cuts are on track.
Less concerning ifTScan shortens its runway from Q4 2027, reports trouble meeting planned cost cuts, or cites a need for near-term financing.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$343 on $10,000 · ±3.4% | How much price usually moves either way. |
| Bad day | $923 loss on $10,000 · 9.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,780 loss on $10,000 · 87.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The Phase 3 study is paused because TScan lacks enough capital. A partner could fund further testing of TSC-101.
Supportive ifTScan names a partner that commits funds. The company also restarts enrollment in ALLOHA-2.
Worry ifNo partner is named, and enrollment remains paused in the next company update.